Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(75.0%)
Early Phase 1
1(25.0%)
4Total
Phase 4(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06656806Early Phase 1Not Yet Recruiting

Efficacy and Safety of Inhaled NC-107 As Compared to Placebo After 4 Weeks of Treatment in Patients with Anxiety

Role: lead

NCT05644769Phase 4Unknown

Chymase Angiotensin-(1-12) Axis In Hypertensive Disease

Role: lead

NCT03826745Unknown

The CHYMASE Angiotensin-(1-12) Axis in Cardiovascular Disease

Role: lead

NCT03635125Phase 4Completed

Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine

Role: lead

NCT03180593Phase 4Completed

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH

Role: lead

All 5 trials loaded